Enterome to present the significant potential of its Mimicry concept, platform and pipeline at BMO’s Biopharma Spotlight Series conference – Immunology and Inflammation

On April 5, 2022 Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial effector-based drug discovery platform, reported that its CEO, Pierre Belichard, will present at the BMO Biopharma Spotlight Series conference on Immunology and Inflammation, which will take place virtually April 6, 2022 (Press release, Enterome, APR 5, 2022, View Source [SID1234611456]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details

Enterome Presentation – Wednesday April 6, 2022 at 1:30 pm EST

Attendee wanting to listen to Enterome (Private) session or other sessions, please access using below.

Link: View Source
Event Code: 2022BSS2 (if prompted)
During the presentation, Dr Belichard will provide an overview of the Company’s Molecular Mimicry concept and rationale that underpins its powerful discovery platform as well as the progress it has made with its advanced OncoMimics and EndoMimics pipelines.